You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 160 No. 1, January 10, 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (82)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Effect of Alendronate on Limited-Activity Days and Bed-Disability Days Caused by Back Pain in Postmenopausal Women With Existing Vertebral Fractures

Michael C. Nevitt, PhD, MPH; Desmond E. Thompson, PhD; Dennis M. Black, PhD; S. R. Rubin, MPH; Kris Ensrud, MD, MPH; A. John Yates, MD; Steven R. Cummings, MD; for the Fracture Intervention Trial Research Group

Arch Intern Med. 2000;160:77-85.

Background  Women with new vertebral fractures have an increased risk of back pain and functional limitation because of back pain. Alendronate sodium treatment reduces the risk of new vertebral fracture by 50% in postmenopausal women with osteoporosis.

Objective  To determine the effect of alendronate therapy on days affected by back pain in postmenopausal women with existing vertebral fractures.

Design  Three-year, placebo-controlled, randomized, double-blind study.

Setting  Fifteen university-based research clinics in the United States.

Participants  A total of 2027 postmenopausal women aged 55 to 81 years with low femoral neck bone density and a preexisting vertebral fracture.

Intervention  Alendronate sodium (5 mg/d for 2 years and 10 mg/d for the third year) or placebo.

Main Outcome Measures  Occurrence and severity of back pain, number of days with back pain, and number of days of bed rest or limited activity because of back pain during 3 years of follow-up.

Results  Irrespective of treatment assignment, women with new, clinically recognized vertebral fractures during follow-up had an increased risk of days of bed disability and days of limited activity because of back pain after the fracture. Women receiving alendronate reported an average of 3.2 fewer days of bed rest (P = .001) and 11.4 fewer days of limited activity (not including days of bed rest) because of back pain (P = .04) during follow-up than those receiving placebo. In the alendronate group, relative to the placebo group, there was a reduced risk of 1 or more bed-rest days (relative risk, 0.68; 95% confidence interval, 0.53-0.87), of 7 or more bed-rest days (0.44; 0.30-0.64), and of 7 or more limited-activity days (0.87; 0.76-0.99). There were no statistically significant differences between treatment groups in the frequency of days of back pain or increases in back-related disability between baseline and study end.

Conclusion  In postmenopausal women with preexisting vertebral fracture, alendronate therapy for 3 years reduced the number of days of bed disability and days of limited activity caused by back pain.


From the Departments of Epidemiology and Biostatistics (Drs Nevitt, Black, and Cummings and Ms Rubin) and Medicine (Dr Cummings), University of California, San Francisco; Scientific Communications Group (Dr Thompson) and Clinical Research (Dr Yates), Merck & Co, Rahway, NJ; and Department of Medicine, Veterans Affairs Medical Center, University of Minnesota, Minneapolis (Dr Ensrud).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(1):121-122.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Vertebrae of Developing Fat-1 Mice Have Greater Strength and Lower N-6/N-3 Fatty Acid Ratio
Lau et al.
Exp. Biol. Med. 2009;234:632-638.
ABSTRACT | FULL TEXT  

Clinical subsequent fractures cluster in time after first fractures
van Geel et al.
Ann Rheum Dis 2009;68:99-102.
ABSTRACT | FULL TEXT  

The effect of alendronate on progression of spinal osteophytes and disc-space narrowing
Neogi et al.
Ann Rheum Dis 2008;67:1427-1430.
ABSTRACT | FULL TEXT  

Minimally Invasive Techniques for the Treatment of Osteoporotic Vertebral Fractures
Manson and Phillips
JBJS 2006;88:1862-1872.
FULL TEXT  

Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date
Hodsman et al.
CMAJ 2002;166:1426-1430.
FULL TEXT  

Restricted Activity among Community-Living Older Persons: Incidence, Precipitants, and Health Care Utilization
Gill et al.
ANN INTERN MED 2001;135:313-321.
ABSTRACT | FULL TEXT  

Risk of New Vertebral Fracture in the Year Following a Fracture
Lindsay et al.
JAMA 2001;285:320-323.
ABSTRACT | FULL TEXT  

Alendronate reduced days of bed rest and limited activity in postmenopausal women with osteoporosis and existing fractures
Johnell
Evid. Based Med. 2000;5:119-119.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.